知證衛生決策工具之十二——查找和使用關于資源利用及成本的研究證據*_《中國循證醫學雜志》

作者：

Andrew D Oxman ¹ , Atle Fretheim ² , John N Lavis ³ , Simon Lewin ⁴

關鍵詞：

DOI：

10.7507/1672-2531.20100420

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

本文我們主要考慮資源利用與成本問題。一項政策或項目方案在資源利用方面的結果與其他方面的影響（如獲益和危害）有所不同。但考慮不同方案的資源利用結果與考慮其他方面的影響類似，因為決策者及其下屬需要確定對資源利用的重要影響，獲得和評價有關這些影響可得的最佳證據，并確保價有所值。當評估某項方案的資源利用及成本結果時，我們建議考慮以下4 個問題：① 對資源利用最重要的影響有哪些？② 現有哪些證據對資源利用有重要影響？③ 資源利用影響的證據可信度有多高？④ 是否對資源利用的影響采用了其真實成本進行恰當賦值？

引用本文： Andrew D Oxman,Atle Fretheim,John N Lavis,Simon Lewin. 知證衛生決策工具之十二——查找和使用關于資源利用及成本的研究證據*. 中國循證醫學雜志, 2010, 10(4): 422-428. doi: 10.7507/1672-2531.20100420 復制

1.	Lavis JN, Oxman AD, Lewin S, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). Introduction. Health Res Policy Syst, 2009, 7(Suppl 1): I1.
2.	Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ, 2008, 336: 1170-1173.
3.	Quon BS, Firszt R, Eisenberg MJ. A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major U.S. drug chain pharmacies. Ann Intern Med, 2005, 143: 397-403.
4.	Russell LB. Opportunity costs in modern medicine. Health Aff(Millwood), 1992, 11: 162-169.
5.	Lavis JN, Oxman AD, Grimshaw J, et al. SUPPORT Tools for evidence-informed healthPolicymaking (STP). 7. Finding systematic reviews. Health ResPolicy Syst, 2009, 7(Suppl 1): S7.
6.	Lewin S, Oxman AD, Lavis JN, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). 11. Finding and using research evidence about local conditions. Health Res Policy Syst, 2009, 7(Suppl1): S11.
7.	Oxman AD, Fretheim A, Lavis JN, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 12. Finding and using research evidence about resource use and costs. Health Res Policy Syst, 2009, 7(Suppl 1): S12.
8.	Brunetti M, Oxman A, Pregno S, et al. GRADE guidelines: 10. Special challenges - resource use. J Clin Epidemiol. in press.
9.	Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes Oxford: Oxford University Press; 2005.
10.	Luce BR, Manning WG, Siegel JE, et al. Estimating costs in costeffectiveness analysis. In Cost-Effectiveness in Health and Medicine Edited by: Gold MR, Siegel JE, Russell LB, Weinstein MC. New York: Oxford University Press; 1996: 176-185.
11.	Lewin S, Oxman AD, Lavis JN, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). 8. Deciding how much confidence to place in a systematic review. Health Res Policy Syst, 2009, 7(Suppl 1): S8.
12.	Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG, 2006, 113: 144-151.
13.	Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important toclinicians? BMJ, 2008, 336: 995-998.
14.	Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care, 2005, 21: 240-245.
15.	Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA, 1999, 282: 1453-1457.
16.	Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA, 2000, 283: 2116-2121.
17.	Palmer S, Raftery J. Economic Notes: opportunity cost. BMJ, 1999, 318: 1551-1552.
18.	Cooper N, Coyle D, Abrams K, et al. Use of evidence in decision models: an appraisal of health technologyassessments in the UK since 1997. J Health Serv Res Policy, 2005, 10: 245-250.
19.	Shemilt I, Mugford M, Byford S, et al. Chapter 15: Incorporating economics evidence. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008) Edited by: Higgins JPT, Green S. The Cochrane Collaboration; 2008.
20.	Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc, 2006, 4: 13.
21.	Oxman AD, Lavis JN, Fretheim A, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 16. Using research evidence in balancing the pros and cons of policies. Health Res Policy Syst, 2009, 7(Suppl 1): S16.
22.	Oxman AD, Lavis JN, Lewin S, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). 10. Taking equity into consideration when assessing the findings of a systematic review. Health Res Policy Syst, 2009, 7(Suppl 1): S10.
23.	Oxman AD, Lavis JN, Fretheim A, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 17. Dealing with insufficient research evidence. Health Res Policy Syst, 2009, 7(Suppl 1): S17.
24.	Fretheim A, Oxman AD, Lavis JN, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 18. Planning monitoring and evaluation of policies. Health Res Policy Syst, 2009, 7(Suppl 1): S18.
25.	O’Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev, 2007, 4: CD000409.
26.	Fretheim A, Oxman AD, Treweek S, et al. Rational Prescribing in Primary Care (RaPP-trial). A randomized trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice. BMC Health Serv Res, 2003, 3: 5.
27.	Fretheim A, Aaserud M, Oxman AD. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice. PLoS Med, 2006, 3: e216.

1. Lavis JN, Oxman AD, Lewin S, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). Introduction. Health Res Policy Syst, 2009, 7(Suppl 1): I1.
2. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ, 2008, 336: 1170-1173.
3. Quon BS, Firszt R, Eisenberg MJ. A comparison of brand-name drug prices between Canadian-based Internet pharmacies and major U.S. drug chain pharmacies. Ann Intern Med, 2005, 143: 397-403.
4. Russell LB. Opportunity costs in modern medicine. Health Aff(Millwood), 1992, 11: 162-169.
5. Lavis JN, Oxman AD, Grimshaw J, et al. SUPPORT Tools for evidence-informed healthPolicymaking (STP). 7. Finding systematic reviews. Health ResPolicy Syst, 2009, 7(Suppl 1): S7.
6. Lewin S, Oxman AD, Lavis JN, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). 11. Finding and using research evidence about local conditions. Health Res Policy Syst, 2009, 7(Suppl1): S11.
7. Oxman AD, Fretheim A, Lavis JN, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 12. Finding and using research evidence about resource use and costs. Health Res Policy Syst, 2009, 7(Suppl 1): S12.
8. Brunetti M, Oxman A, Pregno S, et al. GRADE guidelines: 10. Special challenges - resource use. J Clin Epidemiol. in press.
9. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes Oxford: Oxford University Press; 2005.
10. Luce BR, Manning WG, Siegel JE, et al. Estimating costs in costeffectiveness analysis. In Cost-Effectiveness in Health and Medicine Edited by: Gold MR, Siegel JE, Russell LB, Weinstein MC. New York: Oxford University Press; 1996: 176-185.
11. Lewin S, Oxman AD, Lavis JN, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). 8. Deciding how much confidence to place in a systematic review. Health Res Policy Syst, 2009, 7(Suppl 1): S8.
12. Simon J, Gray A, Duley L. Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG, 2006, 113: 144-151.
13. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important toclinicians? BMJ, 2008, 336: 995-998.
14. Evers S, Goossens M, de Vet H, et al. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care, 2005, 21: 240-245.
15. Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA, 1999, 282: 1453-1457.
16. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA, 2000, 283: 2116-2121.
17. Palmer S, Raftery J. Economic Notes: opportunity cost. BMJ, 1999, 318: 1551-1552.
18. Cooper N, Coyle D, Abrams K, et al. Use of evidence in decision models: an appraisal of health technologyassessments in the UK since 1997. J Health Serv Res Policy, 2005, 10: 245-250.
19. Shemilt I, Mugford M, Byford S, et al. Chapter 15: Incorporating economics evidence. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008) Edited by: Higgins JPT, Green S. The Cochrane Collaboration; 2008.
20. Goldhaber-Fiebert JD, Goldie SJ. Estimating the cost of cervical cancer screening in five developing countries. Cost Eff Resour Alloc, 2006, 4: 13.
21. Oxman AD, Lavis JN, Fretheim A, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 16. Using research evidence in balancing the pros and cons of policies. Health Res Policy Syst, 2009, 7(Suppl 1): S16.
22. Oxman AD, Lavis JN, Lewin S, et al. SUPPORT Tools for evidenceinformed health Policymaking (STP). 10. Taking equity into consideration when assessing the findings of a systematic review. Health Res Policy Syst, 2009, 7(Suppl 1): S10.
23. Oxman AD, Lavis JN, Fretheim A, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 17. Dealing with insufficient research evidence. Health Res Policy Syst, 2009, 7(Suppl 1): S17.
24. Fretheim A, Oxman AD, Lavis JN, et al. SUPPORT Tools for evidence-informed health Policymaking (STP). 18. Planning monitoring and evaluation of policies. Health Res Policy Syst, 2009, 7(Suppl 1): S18.
25. O’Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev, 2007, 4: CD000409.
26. Fretheim A, Oxman AD, Treweek S, et al. Rational Prescribing in Primary Care (RaPP-trial). A randomized trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice. BMC Health Serv Res, 2003, 3: 5.
27. Fretheim A, Aaserud M, Oxman AD. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice. PLoS Med, 2006, 3: e216.

《中國循證醫學雜志》

知證衛生決策工具之十二——查找和使用關于資源利用及成本的研究證據*

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

知證衛生決策工具之十二——查找和使用關于資源利用及成本的研究證據*

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料